Recombinant Human Calcium-binding mitochondrial carrier protein Aralar1 (SLC25A12)

What is the molecular structure of Calcium-binding mitochondrial carrier protein Aralar1?

Aralar1 is an integral membrane protein located in the inner mitochondrial membrane, encoded by the SLC25A12 gene on chromosome 2q31.1. The gene spans 110,902 base pairs and produces a 74.8 kDa protein composed of 678 amino acids . The protein has a distinctive structure with two functional domains:

• N-terminal domain: Contains 2 imperfect EF-hand domains and 3 canonical EF-hand calcium-binding domains that bind calcium in vitro

• C-terminal domain: Contains the mitochondrial carrier regions responsible for transport function

The protein's dual functionality - calcium sensing and metabolite transport - makes it uniquely suited for integrating calcium signaling with metabolic regulation.

What is the primary function of Aralar1 in cellular metabolism?

Aralar1 functions as a mitochondrial electrogenic aspartate/glutamate antiporter that facilitates the exchange of aspartate generated in the mitochondrial matrix for cytosolic glutamate and a proton . This transport activity is a crucial component of the malate-aspartate shuttle (MAS), which represents the main cellular pathway for transferring reducing equivalents of cytosolic NADH into mitochondria .

The transport function is essential for:

• Maintaining oxidative glucose consumption

• Supporting gluconeogenesis from lactate in liver

• Enabling mitochondrial synthesis and export of aspartate to the cytosol

• Supporting critical cellular processes including protein synthesis, and pyrimidine and purine nucleotide production

How does Aralar1 differ from its paralog Citrin (SLC25A13)?

While both Aralar1 (SLC25A12/AGC1) and Citrin (SLC25A13/AGC2) are aspartate-glutamate carriers with similar transport mechanisms, they differ in several significant aspects:

Despite their similarities, these two carriers have evolved distinct physiological roles, with Aralar1 being critical for neural function and Citrin essential for liver metabolism .

What are the recommended methods for detecting Aralar1 protein expression?

For reliable detection of Aralar1 in research contexts, several techniques have been validated:

Western Blotting:

• Recommended antibody dilution: 1/500 for anti-SLC25A12 antibody

• Expected molecular weight: 74 kDa

• Validated sample types: Human cell lines (e.g., HEK-293), rat tissues (heart, kidney), and mouse tissues (kidney, heart)

• Secondary antibody: Goat polyclonal to rabbit IgG at 1/50000 dilution

Immunohistochemistry:

• Recommended antibody dilution: 1/100 for paraffin-embedded tissues

• Validated tissues: Human brain and pancreatic cancer tissue

• Detection method: Standard DAB (3,3-diaminobenzidine) visualization

Immunofluorescence:

• Co-staining with mitochondrial markers (e.g., citrate synthase, 1/500) is recommended

• For dual detection, polyclonal antibody against Aralar (1/500) can be combined with monoclonal antibodies against organelle markers

• DAPI (1 μg/ml) can be used to visualize nuclei

How can researchers measure Aralar1 transport activity in experimental systems?

Measuring the functional activity of Aralar1 requires specialized assays that assess either direct transport or the broader MAS activity:

Malate-Aspartate Shuttle (MAS) Activity Assay:

• Isolate mitochondria from experimental tissue (e.g., liver from 6-7 week-old mice)

• Prepare assay medium containing (in mM): 225 mannitol, 75 sucrose, 10 KCl, 10 Tris-HCl, 5 KH₂PO₄, 0.5 EDTA, and 0.5 EGTA, pH 7.4

• Add mitochondria (0.1-0.25 mg protein/ml), 0.1 mM NADH, 2.5 mM malate, 2 U/ml malate dehydrogenase, 2 U/ml aspartate aminotransferase

• Add calcium when indicated (e.g., 200μM CaCl₂)

• Trigger the reaction with 10 mM glutamate addition

• Measure activity as the NADH decay rate, corrected for glutamate-independent NADH decay

• Normalize to protein content using Bradford method

The expected MAS activity in liver mitochondria expressing Aralar1 is approximately 4-6 nmoles × mg protein⁻¹ × min⁻¹ .

What approaches can researchers use to measure cellular redox status when studying Aralar1 function?

Since Aralar1 is integral to the MAS, which affects cellular redox balance, measuring NADH/NAD⁺ ratios is critical:

Single-cell NADH/NAD⁺ Ratio Measurement:

• Transfect cells with plasmids coding for nuclear ratiometric Peredox-mCherry

• For experimental manipulation of Aralar1 levels, co-transfect with pcDNA3.1-Aralar-Flag

• Use cells 24-36 hours post-transfection

• Preincubate cells in imaging medium (100 mM HEPES, 121 mM NaCl, 4.7 mM KCl, 1.2 mM KH₂PO₄, 1.2 mM MgSO₄, 1.2 mM CaCl₂) supplemented with 2.5-5 mM glucose for 15 minutes

• Perform measurements at 37°C using an inverted microscope with appropriate filters

• Confirm co-transfection by immunocytochemistry in fixed cells at the end of the assay

Notably, research has shown that exogenous Aralar1 expression can reverse the increased NADH/NAD⁺ ratio observed in citrin-deficient cells, demonstrating functional complementation .

What genetic models are available for studying Aralar1 function?

Researchers have developed several genetic approaches to study Aralar1 function:

Transgenic Mouse Models:

• Liver-specific Aralar1 expression: Using the EAlbAAT promoter-intron-aralar-polyadenylation sequence

• Verification method: PCR using primers from β-globin intron and mouse Aralar sequences

• Breeding strategy: Crossing founders with desired genetic background (e.g., citrin-deficient mice)

Cell-based Models:

• Transfection-based overexpression using plasmids like pcDNA3.1-Aralar-Flag

• CRISPR/Cas9 gene editing for knockout or specific mutations

• Verification methods include Western blotting and immunocytochemistry

These models allow for both in vivo and in vitro investigation of Aralar1 functions in different physiological contexts.

How can researchers quantify absolute levels of Aralar1 in tissue samples?

Accurate quantification of Aralar1 is essential for comparative studies across tissues or species:

Absolute Quantification Proteomics Approach:

• Method: Liquid chromatography-mass spectrometry (LC-MS) with parallel reaction monitoring (PRM)

• Standard: AQUA (Absolute Quantification) peptides

• Results: This approach revealed that mouse liver has relatively high endogenous Aralar levels (citrin/aralar molar ratio of 7.8), whereas human liver is virtually devoid of Aralar (CITRIN/ARALAR ratio of 397)

This significant difference in endogenous Aralar levels explains why citrin-deficient mice fail to recapitulate human CITRIN deficiency disease, as they maintain substantial MAS activity through residual Aralar1 .

How are mutations in SLC25A12 linked to neurological disorders?

Mutations in the SLC25A12 gene have significant clinical implications:

Early Infantile Epileptic Encephalopathy 39 (EIEE39):

• Characterized by global hypomyelination of the central nervous system

• Features refractory seizures and neurodevelopmental impairment

• Caused by loss-of-function mutations in SLC25A12

Autism Spectrum Disorders:

• SLC25A12 has established connections to autism

• Research suggests alterations in mitochondrial aspartate export may affect brain development and function

Understanding these disease associations helps direct therapeutic research toward addressing the specific metabolic deficits caused by Aralar1 dysfunction.

Can Aralar1 functionally replace Citrin in therapeutic applications?

Research on the potential for Aralar1 to substitute for Citrin deficiency shows promising results:

Functional Replacement Evidence:

• Exogenous Aralar1 expression in citrin-deficient hepatocytes reverses the increased NADH/NAD⁺ ratio

• Liver mitochondria from citrin-deficient mice expressing transgenic Aralar1 show increased MAS activity (~4-6 nmoles × mg protein⁻¹ × min⁻¹)

• Aralar1 shares 78% identity with Citrin and has similar transport properties, making it a potentially viable replacement

Therapeutic Advantages:

• Using Aralar1 for gene therapy may reduce immune response risks compared to using Citrin

• Aralar1 is expressed in many cell types, including liver Kupffer cells, reducing the likelihood of immune reactivity

This research supports the potential development of Aralar1-based gene therapy approaches for CITRIN deficiency, which includes clinical phenotypes such as neonatal intrahepatic cholestasis (NICCD), failure to thrive and dyslipidemia (FTTDCD), and citrullinemia type II (CTLN2) .

What are the technical challenges in producing functional recombinant Aralar1?

Production of functional recombinant Aralar1 presents several technical challenges:

Expression System Selection:

• Mammalian expression systems are preferred for proper folding and post-translational modifications

• Commonly used vectors include pcDNA3.1 with epitope tags (e.g., Flag) for detection

Functional Verification:

• Western blot confirmation using specific antibodies

• Immunofluorescence to verify mitochondrial localization

• Transport assays to confirm functionality

• NADH/NAD⁺ ratio measurement to verify physiological effect

Common Pitfalls:

• Improper folding leading to non-functional protein

• Interference of tags with calcium-binding domains

• Insufficient mitochondrial targeting

• Potential toxicity from overexpression

How does calcium regulation affect Aralar1 function and how can this be studied?

Calcium regulation is a distinctive feature of Aralar1 function:

Calcium Dependency:

• Aralar1's transport function is dependent on the binding of calcium ions to its N-terminal EF-hand domains

• This calcium sensitivity couples metabolic transport to calcium signaling pathways

Study Approaches:

• Transport assays with varying calcium concentrations

• Site-directed mutagenesis of calcium-binding domains

• Calcium imaging combined with transport measurements

• Comparison of transport activity in calcium-free (EGTA-containing) versus calcium-supplemented conditions

Understanding this calcium regulation is critical for developing comprehensive models of how Aralar1 integrates signaling and metabolism in different physiological contexts.

What are the most promising research directions for Aralar1 studies?

Several key areas represent promising directions for future Aralar1 research:

Therapeutic Development:

• Gene therapy approaches using Aralar1 to treat CITRIN deficiency

• Small molecule modulators of Aralar1 function for neurological disorders

Structural Biology:

• Detailed structural analyses of calcium-binding domains and their interaction with the transport domain

• Structure-based drug design targeting Aralar1

Systems Biology:

• Integration of Aralar1 function into broader metabolic network models

• Understanding tissue-specific roles in different metabolic states

Clinical Translation:

• Biomarker development for Aralar1-related disorders

• Personalized medicine approaches based on patient-specific SLC25A12 variants